“We use cookies on this website to enhance your user experience and to personalise content. By clicking any link or continuing to use our Website you agree to our cookies as per our Privacy Policy. Read More” Ok, I agree

Methadone Hydrochloride (Diskets)

Trade Name : DISKETS

West-Ward Pharmaceuticals Corp.

TABLET

Strength 40 mg/1

METHADONE HYDROCHLORIDE Full Opioid Agonists [MoA],Opioid Agonist [EPC]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Methadone Hydrochloride (Diskets) which is also known as DISKETS and Manufactured by West-Ward Pharmaceuticals Corp.. It is available in strength of 40 mg/1 per ml. Read more

Methadone Hydrochloride (Diskets) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • Warnings and Precautions ()t10/2019
  • Arrayn- Life-Threatening Respiratory Depression
  • Respiratory depression, including fatal cases, have been reported during initiation and conversion of patients to methadone, and even when the drug has been used as recommended and not misused or abused Proper dosing and titration are essential and DISKETS Dispersible Tablets should only be prescribed by healthcare professionals who are knowledgeable in the use of methadone for detoxification and maintenance treatment of opioid addiction. Monitor for respiratory depression, especially during initiation of DISKETS Dispersible Tablets or following a dose increase. The peak respiratory depressant effect of methadone occurs later, and persists longer than the peak pharmacologic effect, especially during the initial dosing period.
  • Arrayn- Risks From Concomitant Use With Benzodiazepines or Other CNS Depressants
  • Concomitant use with benzodiazepines or other central nervous system (CNS) depressants,
  • including alcohol, is a risk factor for respiratory depression and death .
  • Arrayn- Life-Threatening QT Prolongation
  • QT interval prolongation and serious arrhythmia () have occurred during treatment with methadone n n- Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction. Closely monitor patients with risk factors for development of prolonged QT interval, a history of cardiac conduction abnormalities, and those taking medications affecting cardiac conduction for changes in cardiac rhythm during initiation and titration of DISKETS Dispersible Tablets.
  • Arrayn- Accidental Ingestion
  • Accidental ingestion of DISKETS Dispersible Tablets, especially by children, can result in fatal overdose of methadone n
  • Arrayn- Misuse, Abuse, and Diversion of Opioids
  • DISKETS Dispersible Tablets contain methadone, an opioid agonist and Schedule II controlled substance with an abuse liability similar to other opioid agonists, legal or illicit n
  • Arrayn- Interactions with Drugs Affecting Cytochrome P450 Isoenzymes
  • The concomitant use of DISKETS with all cytochrome P450 3A4, 2B6, 2C19, 2C9 or 2D6 inhibitors may result in an increase in methadone plasma concentrations, which could cause potentially fatal respiratory depression. In addition, discontinuation of concomitantly used cytochrome P450 3A4, 2B6, 2C19, or 2C9 inducers may also result in an increase in methadone plasma concentration. Follow patients closely for respiratory depression and sedation, and consider dosage reduction with any changes of concomitant medications that can result in an increase in methadone levels n
  • Arrayn- Conditions For Distribution And Use Of Methadone Products For The Treatment of Opioid Addiction
  • For detoxification and maintenance of opioid dependence, methadone should be administered in accordance with the treatment standards cited in 42 CFR Section 8, including limitations on unsupervised administration n
  • WARNING: LIFE-THREATENING RESPIRATORY DEPRESSION, LIFE-THREATENING QT PROLONGATION, ACCIDENTAL INGESTION, ABUSE POTENTIAL, INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES and TREATMENT FOR OPIOID ADDICTION
  • See full prescribing information for complete boxed warning.
  • Fatal respiratory depression may occur, with highest risk at initiation and with dose increases. Instruct patients on proper administration of DISKETS Dispersible Tablets to reduce the risk. ()
  • Concomitant use with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, and death. (, )
  • QT Interval prolongation and serious arrhythmia () have occurred with treatment with methadone. ()
  • Accidental ingestion of DISKETS Dispersible Tablets can result in fatal overdose of methadone, especially in children. ()
  • DISKETS Dispersible Tablets contain methadone, a Schedule II controlled substance and can be abused and criminally diverted. ()
  • Concomitant use with CYP3A4, 2B6, 2C19, 2C9 or 2D6 inhibitors or discontinuation of concomitantly used CYP3A4, 2B6, 2C19, or 2C9 inducers can result in a fatal overdose of methadone. (, )
  • Methadone products, when used for the treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed only by certified opioid treatment programs as stipulated in 42 CFR 8.12. ()
  • DISKETS Dispersible Tablets contain methadone, an opioid agonist indicated for the:
  • Limitations of Use
  • Methadone products used for the treatment of opioid addiction in detoxification or maintenance programs are subject to the conditions for distribution and use required under 42 CFR 8.12 .
  • DISKETS Dispersible Tablets are an opioid agonist indicated for the:
  • Limitations of Use
  • No data
  • Initiation of Detoxification and Maintenance Treatment:
  • 2.6n- 5.15
  • Maintenance Treatment:
  • 40 mg dispersible tablet for oral administration following dispersion in a liquid: pillow-shaped, light-pinkish orange, cross-scored compressed dispersible tablet.
  • Tablets Intended for Dispersion in a Liquid Immediately Prior to Oral Administration: 40 mg. ()
  • DISKETS Dispersible Tablets are contraindicated in patients with:
  • No data
  • Neonatal Opioid Withdrawal Syndrome:
  • Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients:
  • Serotonin Syndrome:
  • Adrenal Insufficiency:
  • Severe Hypotension:
  • Risks of Use in Patients with Head Injury and Increased Intracranial Pressure:
  • The following serious adverse reactions and/or conditions are described, or described in greater detail, in other sections:
  • The following adverse reactions have been identified during post-approval use of methadone. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposuren
  • The major hazards of methadone are respiratory depression and, to a lesser degree, systemic hypotension. Respiratory arrest, shock, cardiac arrest, and death have occurred.
  • The most frequently observed adverse reactions included lightheadedness, dizziness, sedation, nausea, vomiting, and sweating. These effects seemed to be more prominent in ambulatory patients and in those who are not suffering severe pain.
  • Other adverse reactions include the following:
  • Body as a Whole:
  • Cardiovascular:n- torsade de pointes
  • Central Nervous System:
  • Endocrine:
  • Gastrointestinal:
  • Hematologic:
  • Metabolic:
  • Musculoskeletal:
  • Renal:
  • Reproductive:
  • Respiratory:
  • Skin and Subcutaneous Tissue:
  • Hypersensitivity:
  • Serotonin Syndrome:
  • Adrenal Insufficiency:
  • Anaphylaxis:
  • Androgen Deficiency:n- seen- Clinical Pharmacology ()
  • Most Common Adverse Reactions Are
  • Paradoxical Effects of Antiretroviral Agents on Methadone:
  • Concurrent use of certain protease inhibitors with CYP3A4 inhibitory activity, alone and in combination, such as abacavir, amprenavir, darunavir+ritonavir, efavirenz, nelfinavir, nevirapine, ritonavir, telaprevir, lopinavir+ritonavir, saquinavir+ritonavir, and tipranavir+ritonavir, has resulted in increased clearance or decreased plasma levels of methadone. This may result in reduced efficacy of DISKETS Dispersible Tablets and could precipitate a withdrawal syndrome. Monitor patients receiving DISKETS Dispersible Tablets and any of these anti-retroviral therapies closely for evidence of withdrawal effects and adjust the DISKETS Dispersible Tablets dose accordingly.
  • Effects of Methadone on Antiretroviral Agents:
  • Didanosine and Stavudine:
  • Zidovudine:
  • Effects of Methadone on Antidepressants:
  • Desipramine:
  • Potentially Arrhythmogenic Agents:
  • Interactions with CNS Depressants:
  • Mixed Agonist/Antagonist and Partial Agonist Opioids
  • No data
  • u2022
  • Lactation:
  • 8.2
  • No data
  • Clinical Symptoms:
  • Acute overdosage with methadone can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal-muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension, partial or complete airway obstruction, atypical snoring, and death. Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations . In severe overdosage, particularly by the intravenous route, apnea, circulatory collapse, cardiac arrest, and death may occur.
  • Treatment of Overdose:
  • In case of overdose, priorities are the re-establishment of a patent and protected airway and institution of assisted or controlled ventilation if needed. Employ other supportive measures (including oxygen, vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life support techniques.
  • The opioid antagonists, such as naloxone or nalmefene, are specific antidotes to respiratory depression resulting from opioid overdose. For clinically significant respiratory or circulatory depression secondary to methadone overdose, administer an opioid antagonist. Opioid antagonists should not be administered in the absence of clinically significant respiratory or circulatory depression secondary to methadone overdose.
  • Because the duration of reversal would be expected to be less than the duration of action of methadone, carefully monitor the patient until spontaneous respiration is reliably reestablished. If the response to opioid antagonists is suboptimal or not sustained, administer additional antagonist as directed in the productu2019s prescribing information.
  • In an individual physically dependent on opioids, administration of the recommended usual dosage of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be initiated with care and by titration with smaller than usual doses of the antagonist.
  • DISKETS Dispersible Tablets (Methadone Hydrochloride Tablets for Oral Suspension USP), contain methadone, an opioid agonist, available as 40 mg dispersible tablets for oral administration. Methadone hydrochloride is chemically described as 6-(dimethylamino)-4,4-diphenyl-3-heptanone hydrochloride. Methadone hydrochloride USP is a fine white powder. It is very soluble in water, soluble in isopropanol and in chloroform, and practically insoluble in ether and in glycerine. It is present in DISKETS Dispersible Tablets as the racemic mixture. Methadone hydrochloride has a melting point of 235u00b0C, a pKa of 8.25 in water at 20u00b0C, a solution (1 part per 100) pH between 4.5 and 6.5, a partition coefficient of 117 at pH 7.4 in octanol/water and a molecular weight of 345.91. Its molecular formula is CHNOu2022HCl and its structural formula is:
  • Each DISKETS Dispersible Tablet contains 40 mg of methadone hydrochloride USP and the following inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, orange lake blend, orange/pineapple flavor, potassium phosphate monobasic, pregelatinized starch and stearic acid.
  • DISKETS Dispersible Tablets are cross-scored, allowing for flexible dosage adjustment. Each tablet may be broken or cut in half to yield two 20 mg doses, or in quarters to yield four 10 mg doses.
  • DISKETS Dispersible Tablets (Methadone Hydrochloride Tablets for Oral Suspension USP), are for oral administration following dispersion in a liquid.
  • DISKETS Dispersible Tablets contain insoluble excipients and must not be injected.
  • No data
  • Carcinogenesis:
  • The results of carcinogenicity assessment in B6C2F1 mice and Fischer 344 rats following dietary administration of two doses of methadone HCl have been published. Mice consumed 15 mg/kg/day or 60 mg/kg/day methadone for two years. These doses were approximately 0.6 and 2.5 times a human daily oral dose of 120 mg/day on a body surface area basis (HDD). There was a significant increase in pituitary adenomas in female mice treated with 15 mg/kg/day but not with 60 mg/kg/day. Under the conditions of the assay, there was no clear evidence for a treatment-related increase in the incidence of neoplasms in male rats. Due to decreased food consumption in males at the high dose, male rats consumed 16 mg/kg/day and 28 mg/kg/day of methadone for two years. These doses were approximately 1.3 and 2.3 times the HDD. In contrast, female rats consumed 46 mg/kg/day or 88 mg/kg/day for two years. These doses were approximately 3.7 and 7.1 times the HDD. Under the conditions of the assay, there was no clear evidence for a treatment-related increase in the incidence of neoplasms in either male or female rats.
  • Mutagenesis:
  • There are several published reports on the potential genetic toxicity of methadone. Methadone tested positive in the mouse dominant lethal assay and the mammalian spermatogonial chromosome aberration test. Additionally, methadone tested positive in the DNA repair system and and mouse lymphoma forward mutation assays. In contrast, methadone tested negative in tests for chromosome breakage and disjunction and sex-linked recessive lethal gene mutations in germ cells of Drosophila using feeding and injection procedures.
  • Fertility:
  • Published animal studies show that methadone treatment of males can alter reproductive function. Methadone produces decreased sexual activity (mating) of male rats at 10 mg/kg/day (corresponding to 0.3 times the human daily oral dose of 120 mg/day based on body surface area). Methadone also produces a significant regression of sex accessory organs and testes of male mice and rats at 0.2 and 0.8 times the HDD, respectively. Methadone treatment of pregnant rats from Gestation Day 14 to 19 reduced fetal blood testosterone and androstenedione in males. Decreased serum levels of testosterone were observed in male rats that were treated with methadone (1.3 to 3.3 mg/kg/day for 14 days, corresponding to 0.1 to 0.3 times the HDD) or 10 to 15 mg/kg/day for 10 days (0.8 to 1.2 times the HDD).
  • DISKETS Dispersible Tablets (Methadone Hydrochloride Tablets for Oral Suspension USP)
  • 40 mg supplied as light pinkish orange, pillow shaped, compressed dispersible tablet with product identification u201c54 883u201d debossed on one side and cross scored on the other side.
  • NDC 0054-4538-25: Bottle of 100 Dispersible Tablets
  • DISKETS Dispersible Tablets, if dispensed, must be packaged in child-resistant containers.
  • Store at 25u00b0C (77u00b0F); excursions permitted to 15u00b0 to 30u00b0C (59u00b0 to 86u00b0F) [see USP Controlled Room Temperature].
  • Store DISKETS Dispersible Tablets securely and dispose of properly .
  • Provide the following information to patients receiving DISKETS Dispersible Tablets or to their caregivers:
  • Life-Threatening Respiratory Depression:
  • Discuss the risk of respiratory depression with patients, explaining that the risk is greatest when starting DISKETS Dispersible Tablets or when the dose is increased . Advise patients how to recognize respiratory depression and to seek medical attention if they are experiencing breathing difficulties.
  • Interactions with Benzodiazepines and Other CNS Depressants:
  • Inform patients and caregivers that potentially fatal additive effects may occur if DISKETS Dispersible Tablets are used with benzodiazepines or other CNS depressants, including alcohol. Counsel patients that such medications should not be used concomitantly unless supervised by a healthcare provider .
  • Symptoms of Arrhythmia:
  • Instruct patients to seek medical attention immediately if they experience symptoms suggestive of an arrhythmia (such as palpitations, near syncope, or syncope) when taking DISKETS Dispersible Tablets .
  • Accidental Ingestion:
  • Inform patients that accidental ingestion, especially by children, may result in respiratory depression or death . Instruct patients to take steps to store DISKETS Dispersible Tablets securely. Advise patients to dispose of unused DISKETS Dispersible Tablets by flushing the tablets down the toilet.
  • Abuse Potential:
  • Inform patients that DISKETS Dispersible Tablets contain methadone, a Schedule II controlled substance that is subject to abuse . Instruct patients not to share DISKETS Dispersible Tablets with others and to take steps to protect DISKETS Dispersible Tablets from theft or misuse.
  • Important Administration Instructions [see Dosage and Administration ()]:
  • Instruct patients how to properly take DISKETS Dispersible Tablets, including the following:
  • Serotonin Syndrome:
  • Inform patients that DISKETS could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away if symptoms develop. Instruct patients to inform their physicians if they are taking, or plan to take serotonergic medications .
  • MAOI Interaction:
  • Inform patients to avoid taking DISKETS while using any drugs that inhibit monoamine oxidase. Patients should not start MAOIs while taking DISKETS n
  • Adrenal Insufficiency:
  • Inform patients that DISKETS could cause adrenal insufficiency, a potentially life-threatening condition. Adrenal insufficiency may present with non-specific symptoms and signs such as nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. Advise patients to seek medical attention if they experience a constellation of these symptoms n .
  • Hypotension:
  • Inform patients that DISKETS Dispersible Tablets may cause orthostatic hypotension and syncope. Instruct patients on how to recognize symptoms of low blood pressure and how to reduce the risk of serious consequences should hypotension occur (e.g., sit or lie down, carefully rise from a sitting or lying position) .
  • Anaphylaxis:
  • Inform patients that anaphylaxis has been reported with ingredients contained in DISKETS Dispersible Tablets. Advise patients how to recognize such a reaction and when to seek medical attention n
  • Neonatal Opioid Withdrawal:
  • Advise women that if they are pregnant while being treated with DISKETS, the baby may have signs of withdrawal at birth and that withdrawal is treatable .
  • Lactation:
  • Instruct nursing mothers using DISKETS Dispersible Tablets to watch for signs of methadone toxicity in their infants, which include increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness. Instruct nursing mothers to talk to their babyu2019s healthcare provider immediately if they notice these signs. If they cannot reach the healthcare provider right away, instruct them to take the baby to the emergency room or call 911 (or local emergency services)n
  • Driving or Operating Heavy Machinery:
  • Inform patients that DISKETS Dispersible Tablets may impair the ability to perform potentially hazardous activities such as driving or operating heavy machinery. Advise patients not to perform such tasks until they know how they will react to the medication .
  • Constipation:
  • Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention .
  • Distr. by: n
  • Pharmaceuticals Corp.
  • Eatontown, NJ 07724
  • 10000879/11
  • Revised October 2019
  • NDC 0054-4538-25
  • Rx only

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Desogestrel And Ethinyl Estradiol (Emoquette)

Manufacturer: REMEDYREPACK INC.

Presentation: KIT

Strength:

Pack Size:

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET

Strength: 2.5; .025 mg/1; mg/1

Pack Size:

Fluoxetine Hydrochloride (Fluoxetine)

Fluoxetine Hydrochloride (Fluoxetine)

Manufacturer: REMEDYREPACK INC.

Presentation: CAPSULE

Strength: 40 mg/1

Pack Size:

Metoprolol Succinate (Metoprolol Succinate)

Metoprolol Succinate (Metoprolol Succinate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, EXTENDED RELEASE

Strength: 25 mg/1

Pack Size:

Losartan Potassium (Losartan Potassium)

Losartan Potassium (Losartan Potassium)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, FILM COATED

Strength: 25 mg/1

Pack Size:

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71245 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Get Price

Are you an existing customer or a vendor of GNH India? Log in here to

View your Transaction
COMPANY
SERVICES
QUICK LINKS
CONTACT US
Registered Office Address:

Unit # G- 14, 15, 16, 17, Ground Floor, Prabhadevi Industrial Estate, Enterprises Industrial Premises, 408, Veer Sawarkar Road, Prabhadevi,
Mumbai 400025 India

US Office Address:

GNH Pharmaceuticals USA LLC,
Suite E # 499, 1235 EAST BLVD,
Charlotte, NC, 28203, U.S.A
TEL: +1 704 557 0412

Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.